Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

58.17 -0.03 (-0.06%)

Streaming Delayed Price Updated: 11:31 AM EDT, Aug 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

This Biotech Stock Could Soar on Upcoming Clinical Data ↗

August 04, 2025

This weight loss drugmaker may be significantly undervalued right now.

Via The Motley Fool

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

August 01, 2025

From Genentech

Via Business Wire

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗

July 28, 2025

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.

Via Benzinga

Genentech and Roche Present New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC

July 28, 2025

From Genentech

Via Business Wire

Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms ↗

July 27, 2025

The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid...

Via Stocktwits

The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. ↗

July 26, 2025

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

Via The Motley Fool

Topics Artificial Intelligence Retirement

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗

July 25, 2025

Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward.

Via Stocktwits

Topics Death

Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗

July 23, 2025

The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.

Via Investor's Business Daily

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease

July 21, 2025

From Genentech

Via Business Wire

Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

July 18, 2025

From Genentech

Via Business Wire

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing' ↗

July 11, 2025

Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.

Via Benzinga

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround ↗

July 07, 2025

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.

Via Benzinga

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

Via Investor Brand Network

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. ↗

June 26, 2025

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.

Via Investor's Business Daily

Topics Government

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗

June 25, 2025

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.

Via Investor's Business Daily

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗

June 23, 2025

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

Via Benzinga

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗

June 23, 2025

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.

Via Benzinga

Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗

June 23, 2025

Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.

Via Investor's Business Daily

Two Biotech Stocks Poised For Big Moves On Monday ↗

June 23, 2025

Via Benzinga

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

June 20, 2025

From Genentech

Via Business Wire

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗

June 18, 2025

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.

Via Stocktwits

Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood ↗

June 16, 2025

The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.

Via Stocktwits

Genentech Provides Update on Phase III Verona Study

June 16, 2025

From Genentech

Via Business Wire

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy ↗

June 16, 2025

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Via Benzinga

Topics Death

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease

June 16, 2025

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.